Navigation Links
Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
Date:10/12/2009

SEATTLE, Oct. 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark and Pedro Granadillo have been elected to the Company's Board of Directors. Mr. Clark is currently head of global product strategy and chief marketing officer at Roche, Pharma Division, and, beginning January 1, 2010, he will be chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group. Mr. Granadillo, now retired, was most recently senior vice president of global manufacturing and human resources at Eli Lilly & Company.

"We are pleased to welcome Ian and Pedro to Dendreon's Board of Directors. Their industry leadership experience commercializing significant oncology products and managing large scale pharmaceutical manufacturing facilities make them ideal additions to our Board of Directors as we expand from a research organization into a commercial enterprise," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "Their commercial expertise will strengthen the existing team at Dendreon as we prepare for U.S. Food and Drug Administration approval and the launch of PROVENGE® (sipuleucel-T) next year."

Mr. Clark previously was executive vice president of commercial operations and senior vice president of oncology commercial operations for Genentech's BioOncology business unit, which focused on global commercialization of the company's diverse oncology pipeline, including Avastin®, Rituxan® and Herceptin®. Prior to his time at Genentech, Mr. Clark was president of Novartis Canada and chief operating officer of Novartis United Kingdom. Mr. Clark received a B.S. in biological sciences from Southampton University in the United Kingdom.

Mr. Granadillo worked at Eli Lilly & Company fo
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market survey ... industry . The report firstly reviews the basic ... application and manufacturing technology. The report then explores ... Scanner listing their product specification, capacity, Production value, ...
(Date:8/29/2014)... 2014 The clinical and medical insights provided ... between a product,s success or failure. Despite this, many ... targets – and then to coordinate activities and outreach ... upon which successful KOL engagement rests. ... internal inconsistencies in their KOL management systems and are ...
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements ... the SAM Junctional Tourniquet.  Photo ... Medical Products announced today that it has begun ... a potential issue with a clip used to ... application of the SAM Junctional Tourniquet (SJT).  The ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... , GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- ... release financial results for the fiscal fourth quarter and full ... The company will host a conference call for investors on ... may access the live call by dialing 877-941-9205 (within the ...
... , HARRISBURG, Pa., Nov. 20 The Department of Health ... that did not have previous access to the vaccine. , A total ... hours are from 2 p.m. to 8 p.m. Hours on Saturday, Nov. ... the clinics will operate from 2 p.m. to 8 p.m. , ...
Cached Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2
(Date:9/1/2014)... Texas (PRWEB) September 02, 2014 “Australia ... data on the Australia Hernia Repair market. The report ... units) and average prices (in US dollars) within market ... Meshes and Synthetic 3D Meshes) ,     Composite Meshes ... to a surgical operation for the correction of a ...
(Date:9/1/2014)... with action and sound may be bad for your ... grapes while watching an excerpt from a Hollywood action ... Television has been blamed for helping Americans to gain ... focus of why has been on the medium and ... that can cause people to eat more, including reading, ...
(Date:9/1/2014)... Reinberg HealthDay Reporter ... head-to-head comparison, an experimental drug was more effective than ... failure patients. According to the study authors, the ... of the new drug, dubbed LCZ696. In ... medication, enalapril (Vasotec), either died or were hospitalized due ...
(Date:9/1/2014)... York (PRWEB) September 01, 2014 Liver is ... one vital organ that helps the body in barring itself ... a store of energy. Liver also plays many important functions ... iron and glucose. , Many illnesses can affect the ... under the rib cage on the right side of the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 More than ... added to a federal litigation that continues to progress ... Bernstein Liebhard LLP reports. , A federal Case ... filed over the widely-used cholesterol medication by plaintiffs who ... According to claims, Pfizer Inc. failed to adequately warn ...
Breaking Medicine News(10 mins):Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 2Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 3Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 4Health News:Research letter: Viewers ate more while watching Hollywood action flick on TV 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3
... The infant mortality rate in Orissa would continue to soar ... Suni Naik’s family is still trying to recover after losing ... delivery. // ,Speaking at Talchampei village in tribal-dominated Keonjhar ... They suffered from fever. I took Rs.1,000 from a moneylender ...
... A report published in the January/February issue of General ... journal, says that most children's medicines have the potential ... sugar in them. // ,For example, antihistamine syrups ... low pH levels, which mean that they are high ...
... it has been shown that tomato juice prevented emphysema in ... of the lung-destroying disease. // ,The lung protective ... ,This study appears to be the first to link tomato ... by the researchers, 'We can't simply accept that these results ...
... is greatly increased if an individual has a variant form ... tongue // . The taste receptor gene, called TAS2R16 is ... Washington University School of Medicine have studied more than 262 ... family participated in a study called Collaborative Study of the ...
... his team from University of California, San Francisco using ... sickle cell anemia // in bioengineered mice with healthy ... genes, after therapy it was found that the replaced ... published their work in the Journal Proceedings of the ...
... Department of Health and Human Services reported that very little ... of the illness (bird flu) // . The infection in ... avian influenza. ,Hence to prevent the global pandemic ... of an occurrence of a global pandemic. The government ...
Cached Medicine News:Health News:Poverty Claims Valuable Lives Of Children In Orissa 2Health News:Genetic Variation In Bitter-Taste Receptor Gene Increases Alcoholic Risk 2